β-Blocker use and all-cause mortality of melanoma patients: Results from a population-based Dutch cohort study

European Journal of Cancer

Volumn 49, Issue 18, 2013, Pages 3863-3871

  Livingstone, E ^a   Hollestein, L M ^b   Van Herk Sukel, M P P ^c   Van De Poll Franse, L ^d,e   Nijsten, T ^b   Schadendorf, D ^a   De Vries, E ^b,e  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^d TILBURG UNIVERSITY   (Netherlands)

^e Eindhoven   (Netherlands)

Author keywords

Blocker; Betablocker; Melanoma; Noradrenergic signalling pathway; Pharmacoepidemiology; Survival; Time dependent analysis; Time fixed analysis

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CELIPROLOL; LABETALOL; METOPROLOL; NEBIVOLOL; OXPRENOLOL; PINDOLOL; PROPRANOLOL; SOTALOL;

ADULT; AGED; ARTICLE; CANCER MORTALITY; COMORBIDITY; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; DRUG USE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SURVIVAL RATE;

Β-BLOCKER; BETABLOCKER; MELANOMA; NORADRENERGIC SIGNALLING PATHWAY; PHARMACOEPIDEMIOLOGY; SURVIVAL; TIME-DEPENDENT ANALYSIS; TIME-FIXED ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; AGED; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; REGISTRIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84888000554     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.07.141     Document Type: Article

References (35)

1. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
2. K.T. Flaherty, I. Puzanov, and K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 9 2010 809 819
3. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
4. K.T. Flaherty, J.R. Infante, and A. Daud Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 18 2012 1694 1703
5. S. Lemeshow, H.T. Sorensen, and G. Phillips Beta-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study Cancer Epidemiol Biomarkers Prev 20 10 2011 2273 2279
6. H.H. Grytli, M.W. Fagerland, S.D. Fossa, K.A. Tasken, and L.L. Haheim Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy Prostate 73 3 2013 250 260
7. E.S. Diaz, B.Y. Karlan, and A.J. Li Impact of beta blockers on epithelial ovarian cancer survival Gynecol Oncol 127 2 2012 375 378
8. V. De Giorgi, M. Grazzini, and S. Gandini Treatment with beta-blockers and reduced disease progression in patients with thick melanoma Arch Intern Med 171 8 2011 779 781
9. T.I. Barron, L. Sharp, and K. Visvanathan Beta-adrenergic blocking drugs in breast cancer: a perspective review Ther Adv Med Oncol 4 3 2012 113 125
10. P.H. Thaker, L.Y. Han, and A.A. Kamat Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nat Med 12 8 2006 939 944
11. E.K. Sloan, S.J. Priceman, and B.F. Cox The sympathetic nervous system induces a metastatic switch in primary breast cancer Cancer Res 70 18 2010 7042 7052
12. E.V. Yang, S.J. Kim, and E.L. Donovan Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression Brain Behav Immun 23 2 2009 267 275
13. C.H. Storch, and P.H. Hoeger Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action Br J Dermatol 163 2 2010 269 274
14. K. Masur, B. Niggemann, K.S. Zanker, and F. Entschladen Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers Cancer Res 61 7 2001 2866 2869
15. X. Liao, X. Che, W. Zhao, D. Zhang, T. Bi, and G. Wang The beta-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappaB signaling Oncol Rep 24 6 2010 1669 1676
16. M.P. van Herk-Sukel, L.V. van de Poll-Franse, and V.E. Lemmens New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO record linkage system Eur J Cancer 46 2 2010 395 404
17. L.J. Schouten, P. Hoppener, P.A. van den Brandt, J.A. Knottnerus, and J.J. Jager Completeness of cancer registration in Limburg, The Netherlands Int J Epidemiol 22 3 1993 369 376
18. R.M. Herings, A. Bakker, B.H. Stricker, and G. Nap Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts J Epidemiol Community Health 46 2 1992 136 140
19. H.S. Lau, A. de Boer, K.S. Beuning, and A. Porsius Validation of pharmacy records in drug exposure assessment J Clin Epidemiol 50 5 1997 619 625
20. H. Buurma, M.L. Bouvy, P.A. De Smet, A. Floor-Schreudering, H.G. Leufkens, and A.C. Egberts Prevalence and determinants of pharmacy shopping behaviour J Clin Pharm Ther 33 1 2008 17 23
21. C.M. Balch, J.E. Gershenwald, and S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 2009 6199 6206
22. WHO. Definition and general considerations. In: Methodology WCCfDS, editor. Oslo: WHO; 2009.
23. R. Ruiter, L.E. Visser, and M.P. van Herk-Sukel Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study Diabetologia 55 1 2012 51 62
24. B.H. Stricker, and T. Stijnen Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies Eur J Epidemiol 25 4 2010 245 251
25. E. de Vries, T.E. Nijsten, and O. Visser Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site Ann Oncol 19 3 2008 583 589
26. E. de Vries, S. Houterman, and M.L. Janssen-Heijnen Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands Ann Oncol 18 6 2007 1110 1116
27. T. Hakulinen, and K.H. Abeywickrama A computer program package for relative survival analysis Comput Program Biomed 19 2-3 1985 197 207
28. S. Suissa Immortal time bias in pharmaco-epidemiology Am J Epidemiol 167 4 2008 492 499
29. S.W. Cole, and A.K. Sood Molecular pathways: beta-adrenergic signaling in cancer Clin Cancer Res 18 5 2012 1201 1206
30. M. Sanzo, R. Colucci, M. Arunachalam, S. Berti, and S. Moretti Stress as a possible mechanism in melanoma progression Dermatol Res Pract 2010 2010 483493
31. M. Wolkewitz, A. Allignol, S. Harbarth, G. de Angelis, M. Schumacher, and J. Beyersmann Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias J Clin Epidemiol 65 11 2012 1171 1180
32. A.V. Chobanian, G.L. Bakris, and H.R. Black The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report JAMA 289 19 2003 2560 2572
33. K. Lang, Tl 4th Drell, and A. Lindecke Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs Int J Cancer 112 2 2004 231 238
34. C. Smith, and M. Teitler Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors Cardiovasc Drugs Ther 13 2 1999 123 126
35. V. De Giorgi, M. Grazzini, and S. Gandini Beta-adrenergic-blocking drugs and melanoma: current state of the art Expert Rev Anticancer Ther 12 11 2012 1461 1467